Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Johnson & Johnson filings on SEC EDGAR ↗
Johnson & Johnson reported 2,407,310,266 shares of common stock outstanding as of October 15, 2026. The filing outlines the company's financial results for the fiscal third quarter and nine months ended September 27, 2026, while highlighting strategic risks including the planned separation of its Orthopaedics business.
Johnson & Johnson reported Q3 2026 sales growth of 5.9% to $25.4 billion, driven by strong performance in its Innovative Medicine and MedTech segments. The company raised its full-year 2026 guidance for both sales and adjusted EPS, despite a GAAP earnings impact from a one-time special charge related to talc litigation and recent M&A activity.
Term
Q3 2026
“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio.”
Joaquin Duato, Chairman and Chief Executive Officer
“This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.”
Joaquin Duato, Chairman and Chief Executive Officer